

+ z + + z + z + z + z + z + ;

November 2019





- 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Oventus Medical Limited ACN 608 393 282 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
- 2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
- 3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
- 4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
- 5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.





- Commercial stage medtech/device company leveraging O₂Vent[®] platform technology to disrupt the obstructive sleep apnoea (OSA) treatment landscape
- O₂Vent[®] is the only FDA-cleared oral therapy for OSA which combines efficacy of gold standard without a face mask, and the simplicity / compliance of Mandibular Advancement Devices
- Not reliant upon any clinical trial outcomes: solid, peer reviewed data in place
- Ramping-up US commercial operations post Sept 2019 FDA approval of O_2 Vent [®] Optima:
 - 29 sites signed; 5 deployed and 8 undergoing deployment currently. Minimum quotas of 20 devices per site, per month, once fully operational
 - Revenues set to ramp up from December quarter onwards
- Fully focused on roll out in key markets of US and Canada and Australia. North American 'lab in lab' business model game-changing







Obstructive Sleep Apnoea overview

- Obstructive sleep apnoea (OSA) is the most common type of 'sleep apnoea'
- OSA is the absence of breathing that occurs during sleep that results in disruptive sleep
- Compromises daytime functions leading to excessive sleepiness, memory impairment, depression and a host of co-morbidities, eg. hypertension, heart disease, stroke and diabetes etc.
- Occurs when there is obstruction or collapse of the nose, soft palate and lateral walls of the airway



Key indicator: snoring



Risk factor for chronic disease



Cost burden \$149.6B, \$6,033 per person per year undiagnosed






How has OSA historically been treated?


How it works Comment Efficacy Treatment type Standard of care is Continuous Patient wears mask and is Works well sometimes. 100%¹ but poorly tolerated by Positive Airway Pressure (CPAP) hooked up to machine. Blows air into throat, forcing airways majority of patients to open Mandibular Advancement Like a mouthguard. Brings the Works for some 56%¹ mandible forward, altering jaw patients, but ~50% Devices and tongue position require more treatment Mixed Surgery Intended to remove obstruction Complex and prone to failure. Failure leads to results in patients' upper respiratory tracts worse problems Mixed Weight loss Losing weight can help with Not always readily achievable results reducing apnoea in some cases Mixed Other/Behavioural modification Sleep position, reduced alcohol Requires patient results consumption, medication motivation and compliance





Limitations of CPAP - standard of care





Pressure intolerance and device noise



Limits freedom of movement with the power cords and mask hose



Cleaning, maintenance and resupply.





- The increase in nasal airway resistance can lead to mouth breathing.¹ Mouth breathing leads to CPAP intolerance.
- What drives nasal congestion?
 - Allergies
 - Congestion
 - Deviated septum
 - Anatomical features
 - Other issues

"The importance of the nose to successful use of CPAP cannot be overstated."

- Dr. Jerrold A. Kram, MD, FCCP, FAASM



©2019 Oventus Medical Limited

1 McNicholas WT. The nose and OSA: variable nasal obstruction may be more important in pathophysiology than fixed obstruction. Eur Respir J. 2008 Jul;32(1):3-8.



The alternative to CPAP...

 $_{\rm cont}$... if you can't use your nose, get yourself a second one and breathe again using the O2Vent $^{\circ}$

O2Vent[®] Optima is an oral appliance for patients diagnosed with Obstructive Sleep Apnea and who are seeking alternatives to CPAP therapy.







O₂Vent Airway Technology

...near CPAP efficacy without the need for a mask

Standard MAD devices

56%¹



- Oral appliance brings lower jaw forward
- Efficacy significantly lower than CPAP
- Much higher compliance rates than CPAP



80%1 O₂Vent™ Optima ExVent™ valve

Oventus Airway Technology

- Oral appliance with Oventus Airway Technology and brings jaw forward similarly to MAD* devices
- Near CPAP efficacy
- Regulates breathing pressure between nose and mouth
- Acts like a second nose
- Much higher compliance rates than CPAP

CPAP - standard of care

100%¹



• Pressurising breathing airway with mask

- Highly efficacious
- Not well tolerated poor patient compliance and comfort
- Discomfort of high pressure and mask
- Lack of portability, air leakages and noise

O2Vent®'s product evolution plan: completely eliminates the need of a full-face mask for CPAP







- Company's success connected solely to commercial execution
 - Investors face no clinical trial inflection point (binary events)
 - Recent FDA clearance of O₂Vent[®] Optima allows new investor(s) to benefit fully in the upside potential given low current market cap
 - Management has track record of creating and optimising dental practices
- Commercial strategy clearly defined due to feedback from 1st-gen device
 - "Low hanging fruit" opportunity for O₂Vent[®] given 3 million dissatisfied CPAP users
 - Contracting with just 5 central sleep networks taps into >1m new diagnoses per year
 - 5% of unsatisfied CPAP user population generates \$75M in revenues



Oventus offers **the <u>only</u> highly effective,** non-invasive OSA treatment

Based on the numbers below, Oventus could have a \$2b market in the US alone

12%¹ of US adults (29.4m) suffer from OSA (US 55% of global market)

- ~6M adult patients prescribed CPAP in the US alone. 50-60% of those patients quit CPAP
 - ~3M existing patients in need of an effective alternative treatment
 - Oventus devices sold wholesale for ~\$600/unit to sleep centres
 - Valves/other accessories drive recurring revenues

Oral appliances currently have 10% share This number predicted to grow a further 16% by 2025



¹Based on 12% prevalence in adults within US suffering OSA as defined by having five or more sleep events per hour (AHI>5). Source: Primary research with experts, U.S. Census (2014), Peppard "Increased Prevalence of Sleep-disordered Breathing in Adults." American

©2019 Oventus Medical Limited

COCEAN



Oventus is set to disrupt the sleep industry

Why do oral appliances only represent 10% of the therapeutic market?

• Variable efficacy of oral appliances



• Complex patient journey



 Competing economic imperatives between the sleep and dental channels How will Oventus increase the market share of oral appliances?


- Oventus has been clinically validated to be the most effective oral appliance available with success rates comparable to CPAP
- Oventus' digital workflow and virtual patient journey mean that Oventus' unique treatment modality can be delivered in both the sleep and dental Channel
- Oventus' lab in lab program increases revenue and profit for both the sleep and dental channel





Traditional patient journey

+ + z + z + z + z + z <u>+ z</u>





Oventus 'lab in lab' model is designed to simplify the patient experience and build value for all stakeholders

- Model provides support, training and resources required to run a professional Dental Sleep Medicine clinic in both the dental and sleep setting
- Utilises Oventus' $\mathrm{O}_{2}\mathrm{Vent}$ sleep treatment platform and digital workflow
- Minimal CAPEX required. Can get lab up and running with desktop scanner
- Creates a new sub-specialty of sleep-dentists working out of sleep facilities or in their own clinics with turnkey support










Oventus simplified patient journey with strategic partners and lab in lab model














By enabling dentists to take oral scans of patients mouths within the sleep facility (under a low capex mode), the patient is able to complete their whole care cycle at the one location.



Dentist within sleep centre* scans patient for O₂Vent, delivers device, handles reimbursement

Patient returns to sleep doc for follow up consultations



This significantly improves what until now has been a highly fragmented clinical experience for patients



* Traditional model sees patient visit dentist multiple times.

©2019 Oventus Medical Limited



By enabling sleep physicians to diagnose and manage patients' OSA within the dental channel (via telemedicine and home sleep testing), the patient is able to complete their whole care cycle at the one location.

Sleep physician consults/diagnoses/prescribes via telemedicine Dentist within dental clinic scans patient for O₂Vent, delivers device, handles reimbursement Patient care is followed up by dentist at dental clinic and sleep physician via telemedicine



This significantly improves what until now has been a highly fragmented clinical experience for patients



What is driving adoption of 'lab in lab' model?

- Supports the patient's treatment journey from end to end to ensure they patient receive the benefit of Oventus Airway Technology when indicated
- This 'lab-in-lab' model can increase revenue and profit for both the dentist and sleep groups and improve clinical outcomes for patients
- Sleep networks will prescribe an Oventus device because it delivers oral appliance adherence rates with efficacy comparable to CPAP, with higher profit margins than CPAP
- Contracted dentists will generate significantly higher net revenue, per session using the 'lab in lab' model in the sleep channel






Oventus Technology Adoption and 'Lab in Lab' Roll Out

- 22 contracted sites in the US with mandated minimum orders of 20 devices per site
- 7 contracted sites in Canada with mandated minimum orders of 20 devices per month per site
- Significant "funnel" of sleep facilities in negotiation across North America for lab in lab with 5 sites operational now, a further 8 sites in the implementation phase and a robust pipeline of launches scheduled for the remainder of calendar 2019 and into 2020
- Lead times to first revenue from launch is sixty days with ninety days to build to minimum quotas
- Strategic agreements with Virtuox, Lyon Dental Billing and Carestream Dental to facilitate Lab in Lab model in both sleep and dental channels
- Manufacturing transfer to US for North American market scheduled for end of November to reduce turn around time and COGS



Current lab in lab "deal funnel" worth >\$20M annualised and growing rapidly



Timeline of significant events

	1H CY	2019	2H CY2019	CY2020	
		4 sleep/dental sites in North Carolina sign on to sell O ₂ Vent [™] W/T models (22 May)	Strong pipeline of negotiations with Canadian, US and Australian groups		
Major contracts			First sleep group signed in US (15 July). Subsequent agreements	Agreements signed	
		First sleep groups signed in Canada across 7 sites (20	signed, now 29 sites contracted in US/Canada.	Agreements signed	
		June) for O₂Vent™ Optima & ExVent™	Material contracts signed (16 July) to enable 'lab in lab' across both	Agreements signed	
			sleep and dental in US		
	Australia	Canada	US	US	
Product launches	O₂Vent™ Optima (nylon) Launched Jan 2019 (TGA registered) ☑	O₂Vent™ Optima (nylon) Launched Feb 2019* ☑	O₂Vent [™] Optima (nylon), launch expected in 2H CY2019 (awaiting FDA approval)	ExVent [™] valve Launch expected in CY2020	
			Australia		
			ExVent [™] valve Launched June 2019 (TGA registered) ☑		
Ä	*Canada recognises Australia's TG		Canada		
	©2019 Oventus Medical Lir		ExVent™ valve	22	

US Oventus Team



Robin Randolph

Sr VP Sales, Marketing and Operations Marketing & Sales executive 30+ years Sleep Industry. In-depth North America medical device commercialization experience. Former Dir. Sleep Initiatives and National Accounts- ResMed, Manager-Fisher & Paykel Healthcare NA Marketing



Masoud Vahidi

VP Operations, North America 15+ years leadership experience in upstream and downstream marketing of medical devices in sleep apnoea, COPD, and dental Restoratives products. Former Sr. Marketing Manager - KaVo Kerr



Phillip Miller

Leader Information Technology Proven leadership 20+ years information technology systems and services across a range of industries and markets. Former VP Data & Communications -ResMed





Robyn Woidtke, MSN-Ed, RN, BSHS, R.PSGT Director of Regulatory and Clinical Affairs

With a sleep medicine career spanning 30 years and extensive experience in the medical device industry. Former Director of Clinical Affairs - ResMed



David Bonenko

Vice President, Sales Several decades of sales leadership and 10+ years' experience in the sleep medicine industry. Previously was VP Sales for SleepMed.



Peggy Powers

Manager Clinical Education

20+ years clinical educator and authority in the sleep & respiratory industry. Registered Respiratory Therapist. Former Manager Clinical Education -ResMed, former Clinical Educator - Fisher & Paykel Healthcare



Brian Ueda

Marketing Operations Manager

10+ years marketing career with extensive marketing operations and digital marketing experience in the medical device industry. Former Digital Marketing Manger - Fisher & Paykel Healthcare

US Medical Technology Advisory Board

Key opinion leaders, clinicians and corporate experts in sleep medicine



Dr. Lee A. Surkin, MD, FAASM Chief Medical Officer of N3Sleep



Dr. Mark A. Rasmus, MD, FAASM Medical Director, Idaho Sleep Health

Jerrold A. Kram, MD,

Medical Director of the

California Centre for

FCCP, FAASM

Sleep Disorders



Daniel B. Brown, Esq. Partner, Healthcare and Corporate Practice Groups, Taylor English Duma LLP Atlanta, Georgia



Dr. Richard K. Bogan, MD, FCCP, FAASM Associate Clinical Professor at the University of South Carolina School of Medicine in Columbia, SC and Medical University of SC in Charleston, SC



Pedro J. Cuartas, DDS Clinical Director of South LA Dental Sleep Medicine Owner-- Dental Sleep Services, LLC



Dr. Mark Hickey, MD, FAASM Founder, Colorado Sleep Institute



Myra G. Brown President, MbrownGroup LLC

Finances - Corporate overview, ASX: OVN

Cash on hand 30 Sept 2019	\$8,370,516
---------------------------	-------------

\$828,000 R&D Tax incentive received 6 Nov 2019

\$332,000 Revenue FY2019 (ending 30 June 2019)

Receipts from customers (Qtr end 30 Sept 2019) \$87,000

Capital structure

Shares on issue	130.53m
Options	4.48m
Share price (22 November 2019)	\$0.55
Market Cap (22 November 2019)	\$71.79

Shareholders

Dr Chris Hart	20%
Other founders	8%
Other top 20 shareholders	31%
Remaining shareholders	41%

Remaining shareholders

\$0.81

\$0.69-\$0.57 \$0.44 \$0.32 \$0.20

3.0 -

- Price (AUD) Volume (m) 2.5-1.5-1.0-0.0-23 Jan 19 08 May 19 19 Dec 18 27 Feb 19 03 Apr 19 12 Jun 19 17 Jul 19 21 Aug 19 25 Sep 19 30 Oct 19





- Technology is clinically validated as **the most effective oral appliance for sleep apnoea** with treatment outcomes comparable to CPAP
- **Huge unmet medical need** with sleep apnoea treatment market worth >\$US3 billion and forecast to grow substantially
- Company is at the **key critical commercialisation point** in key markets of the US, Canada and Australia
- Demonstrating interest: lab in lab **contracts with minimum quotas signed** / announced in June and second half of calendar 2019, now 29 sites engaged with 5 deployed and 8 in implementation phase
- Launch of the lab in lab business model set to **increase sales revenue in the second half** of calendar 2019 and enable greater adoption of Oventus' Sleep Treatment Platform
- Positioned for **significant revenue growth** well in to CY2020 due to a robust pipeline of additional agreements

Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98. China data - Anti-snoring Devices and Snoring Surgery Market: 2016-2024 https://www.marketsandmarkets.com/Market-Reports/sleep-apnea-devices-market-719.html





Oventus Airway Technology

This is what our patients say about comfort when compared to a traditional oral device

"Due to my new Oventus device I have found that I am sleeping far better. Previously I had a sleep apnoea machine with a long hose and a nose piece. I was constantly battling with the hose because I felt like it was always pulling on my head. I was waking most mornings with a dry mouth and bloated stomach from the machine forcing air. I travel often and found it challenging to bring my machine with me. These things are no longer an issue thanks to my new Oventus device." Blake Schampers

"The Oventus device allowed me to sleep in a normal manner without my sleep being interrupted by leaking and ill-fitting masks. The Oventus device is also so much more easily mobile than machines and masks especially when travelling." David Nicoll









Dr Chris Hart Founder & CEO <u>chris@oventus.com.au</u> +61 409 647 496





+ z + z + z

©2019 Oventus Medical Limited

Intellectual Property: expiry dates between 2032-2039





Multiple domain names registered

Trademarks advancing according to Madrid protocol



Appliance validation - O_2 Vent (Oventus Airway Technology)

Clinical trials to validate Oventus 'airway technology' and assist marketing

Name	Study/ Investigation	Patients completed (per Nov 2018)	Results - reduction in A (sleep events per hour)		Events
Sydney study (NeuRa) OVEN-005 CRC-P funded (\$2.95m) 3 stages over 3 years 180 Patients in Total	Pilot study	4	37 reduced to 8 = 78% reduction Airway Technology increased efficacy by 50% cf Traditional oral appliance	In addition to AHI reduction, 66% reduction in CPAP pressure required when using Oventus CPAP connector	Presented at AADSM/AASM Sleep 2017 in Boston
	Nasal Resistance Study	7 39	34.4 reduced to 7.0 = 80% reduction 29 reduced down to 14.5 = 50% reduction	Increased nasal resistance did not impact treatment outcomes	Interim results presented at Prague, World Sleep Congress (abstract) 9-12 October 2017 Expanded results presented at European Respiratory Society in Paris September 2018
	PEEP Valve Study	22	21.6 reduced to 7.2 67% reduction In previous treatment failures	Success rates increased by 59% enabling over 75% of patients to be treated successfully without CPAP	Final results being presented at the ASA Sleep DownUnder Oct 2018 Published in <i>SLEEP</i> June 2019
	MAS Combo Study	16	CPAP Pressure requirements reduced by 35-40%	Patients able to breathe through the device while using nCPAP eliminating the need for full face masks	Interim results presented at European Respiratory Society in Paris September 2018 Expanded results presented at ASA Sleep DownUnder Oct 2018



Appliance validation - O₂Vent (Oventus Airway Technology)

Clinical trials to validate Oventus 'airway technology' and assist marketing

Name	Study/ Investigation	Patients completed (per Nov 2018)	Results - reduction in AHI (sleep events per hour)*	Commentary	Peer Review
Perth study OVEN-004	Airway Open/Airway Closed	10	69.6 reduced to 19.4 = 72% reduction	Airway Technology increased Efficacy by 30 %	Interim results: Auckland Sleep DownUnder, ASA Conference (abstract) 25 October 2017
Effect of Oventus Airway on Upper airway Physiology	Predictors of response to Oventus Airway	22**	53.6 reduced to 29.4 = 45% reduction	Physiologic Study showing females exhibited greater response to Oventus Airway Technology	Final results presented at the ASA Sleep DownUnder Oct 2018
Brisbane study OVEN-003	Effect of Oventus Airway on Efficac & Compliance		24 reduced to 10 = 58% reduction	Airway Technology increased response rate by 40% and success rate by 20% Increased efficacy in nasal obstructers and previous treatment failures	Final results presented at the ASA Sleep DownUnder Oct 2018
Brisbane study OVEN-001	Efficacy of Oventus O ₂ Vent	29	42 reduced to 16 = 62.5% reduction	Same response rate and efficacy with and without self reported nasal congestion	Journal of Dental Sleep Medicine, Vol 4, No. 3

Total patients

171



* Apnoea-Hypopnoea Index (AHI), known as 'sleep events' per hour occurring when the breathing airway collapses temporarily, leading to disruptions in breathing and sleep, in patients with Obstructive Sleep Apnoea (OSA)

** 10 patients data on this study were presented previously in Auckland Sleep DownUnder ASA Conference



About Oventus

+ z + + z + z + z + z + z + z Oventus is an Australian medical device company with a proprietary technology for the treatment of *obstructive sleep apnoea (OSA)*. Our focus is on treating those patients that are not being, or cannot be treated effectively with existing treatment modalities.

OSA is a massive, multibillion dollar and fast-growing market

There is a huge unmet need many times the size of the existing market due to the abandonment of existing treatments by the majority of patients

Oventus has a clinically proven ability to deliver superior outcomes for more than 80% of these patients with the first products in its treatment platform currently launching in the US with FDA clearance and existing reimbursement codes

Platform technology developed and company founded in 2013 by CEO, Dr Chris Hart B.Sc. B.D.Sc (Hons) M.Phil (Cantab), Oventus is listed on the Australian Securities Exchange (ASX:OVN)